169 related articles for article (PubMed ID: 20926616)
1. Physiological basis for inhibition of morphine and improgan antinociception by CC12, a P450 epoxygenase inhibitor.
Heinricher MM; Maire JJ; Lee D; Nalwalk JW; Hough LB
J Neurophysiol; 2010 Dec; 104(6):3222-30. PubMed ID: 20926616
[TBL] [Abstract][Full Text] [Related]
2. Brain P450 epoxygenase activity is required for the antinociceptive effects of improgan, a nonopioid analgesic.
Hough LB; Nalwalk JW; Yang J; Conroy JL; VanAlstine MA; Yang W; Gargano J; Shan Z; Zhang SZ; Wentland MP; Phillips JG; Knapp BI; Bidlack JM; Zuiderveld OP; Leurs R; Ding X
Pain; 2011 Apr; 152(4):878-887. PubMed ID: 21316152
[TBL] [Abstract][Full Text] [Related]
3. CC12, a P450/epoxygenase inhibitor, acts in the rat rostral, ventromedial medulla to attenuate morphine antinociception.
Conroy JL; Nalwalk JW; Phillips JG; Hough LB
Brain Res; 2013 Mar; 1499():1-11. PubMed ID: 23298831
[TBL] [Abstract][Full Text] [Related]
4. Neural basis for improgan antinociception.
Heinricher MM; Martenson ME; Nalwalk JW; Hough LB
Neuroscience; 2010 Sep; 169(3):1414-20. PubMed ID: 20570607
[TBL] [Abstract][Full Text] [Related]
5. CC12, a high-affinity ligand for [3H]cimetidine binding, is an improgan antagonist.
Hough LB; Nalwalk JW; Phillips JG; Kern B; Shan Z; Wentland MP; de Esch IJ; Janssen E; Barr T; Stadel R
Neuropharmacology; 2007 Apr; 52(5):1244-55. PubMed ID: 17336343
[TBL] [Abstract][Full Text] [Related]
6. Improgan-induced hypothermia: a role for cannabinoid receptors in improgan-induced changes in nociceptive threshold and body temperature.
Salussolia CL; Nalwalk JW; Hough LB
Brain Res; 2007 Jun; 1152():42-8. PubMed ID: 17433267
[TBL] [Abstract][Full Text] [Related]
7. Pain-facilitating medullary neurons contribute to opioid-induced respiratory depression.
Phillips RS; Cleary DR; Nalwalk JW; Arttamangkul S; Hough LB; Heinricher MM
J Neurophysiol; 2012 Nov; 108(9):2393-404. PubMed ID: 22956800
[TBL] [Abstract][Full Text] [Related]
8. Kappa opioids inhibit physiologically identified medullary pain modulating neurons and reduce morphine antinociception.
Meng ID; Johansen JP; Harasawa I; Fields HL
J Neurophysiol; 2005 Mar; 93(3):1138-44. PubMed ID: 15456805
[TBL] [Abstract][Full Text] [Related]
9. Antinociception and modulation of rostral ventromedial medulla neuronal activity by local microinfusion of a cannabinoid receptor agonist.
Meng ID; Johansen JP
Neuroscience; 2004; 124(3):685-93. PubMed ID: 14980738
[TBL] [Abstract][Full Text] [Related]
10. Circuitry underlying antiopioid actions of cholecystokinin within the rostral ventromedial medulla.
Heinricher MM; McGaraughty S; Tortorici V
J Neurophysiol; 2001 Jan; 85(1):280-6. PubMed ID: 11152727
[TBL] [Abstract][Full Text] [Related]
11. Microinjection of morphine into various amygdaloid nuclei differentially affects nociceptive responsiveness and RVM neuronal activity.
McGaraughty S; Heinricher MM
Pain; 2002 Mar; 96(1-2):153-62. PubMed ID: 11932071
[TBL] [Abstract][Full Text] [Related]
12. The role of excitatory amino acid transmission within the rostral ventromedial medulla in the antinociceptive actions of systemically administered morphine.
Heinricher MM; McGaraughty S; Farr DA
Pain; 1999 May; 81(1-2):57-65. PubMed ID: 10353493
[TBL] [Abstract][Full Text] [Related]
13. Activation of brainstem N-methyl-D-aspartate receptors is required for the analgesic actions of morphine given systemically.
Heinricher MM; Schouten JC; Jobst EE
Pain; 2001 May; 92(1-2):129-38. PubMed ID: 11323134
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of improgan antinociception by the cannabinoid (CB)(1) antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): lack of obligatory role for endocannabinoids acting at CB(1) receptors.
Hough LB; Nalwalk JW; Stadel R; Timmerman H; Leurs R; Paria BC; Wang X; Dey SK
J Pharmacol Exp Ther; 2002 Oct; 303(1):314-22. PubMed ID: 12235266
[TBL] [Abstract][Full Text] [Related]
15. Circuitry underlying antiopioid actions of orphanin FQ in the rostral ventromedial medulla.
Heinricher MM; McGaraughty S; Grandy DK
J Neurophysiol; 1997 Dec; 78(6):3351-8. PubMed ID: 9405549
[TBL] [Abstract][Full Text] [Related]
16. Antinociceptive activity of CC44, a biotinylated improgan congener.
Hoerbelt P; Nalwalk JW; Phillips JG; Wentland MP; Shan Z; Hough LB
Eur J Pharmacol; 2013 Aug; 714(1-3):464-71. PubMed ID: 23834775
[TBL] [Abstract][Full Text] [Related]
17. A role for spinal, but not supraspinal, alpha(2) adrenergic receptors in the actions of improgan, a powerful, non-opioid analgesic.
Svokos K; Nalwalk JW; Leurs R; Menge WM; Timmerman H; Hough LB
Brain Res; 2001 Dec; 923(1-2):12-9. PubMed ID: 11743967
[TBL] [Abstract][Full Text] [Related]
18. Disinhibition of off-cells and antinociception produced by an opioid action within the rostral ventromedial medulla.
Heinricher MM; Morgan MM; Tortorici V; Fields HL
Neuroscience; 1994 Nov; 63(1):279-88. PubMed ID: 7898652
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of improgan, a non-opioid analgesic, in neuropathic pain.
Albrecht PJ; Nalwalk JW; Hough LB
Brain Res; 2011 Nov; 1424():32-7. PubMed ID: 22015352
[TBL] [Abstract][Full Text] [Related]
20. Antinociceptive activity of chemical congeners of improgan: optimization of side chain length leads to the discovery of a new, potent, non-opioid analgesic.
Hough LB; de Esch IJ; Janssen E; Phillips J; Svokos K; Kern B; Trachler J; Abood ME; Leurs R; Nalwalk JW
Neuropharmacology; 2006 Sep; 51(3):447-56. PubMed ID: 16806300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
